Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17995453
Chen S, et al. (2008) Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators. Biochem J 409, 449-59 17995453
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S237-p - TBC1D1 (human)
Modsite: RPMRKsFsQPGLRSL SwissProt Entrez-Gene
Orthologous residues
TBC1D1 (human): S237‑p, TBC1D1 iso2 (human): S237‑p, TBC1D1 (mouse): S231‑p, TBC1D1 iso2 (mouse): S231‑p, TBC1D1 (rat): S231‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  human, rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE AMPKA1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE AMPKA1 (human) modification site within consensus motif, pharmacological activator of upstream enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LY294002 increase
phenformin increase
A23187 increase
A-769662 increase
IGF-1 no change compared to control
wortmannin no change compared to control
EGF no change compared to control
phorbol_ester no change compared to control
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
14-3-3 sigma (human) Induces far-Western, co-immunoprecipitation

S263-p - TBC1D1 (human)
Modsite: RSSGFFSsFEESDIE SwissProt Entrez-Gene
Orthologous residues
TBC1D1 (human): S263‑p, TBC1D1 iso2 (human): S263‑p, TBC1D1 (mouse): S256‑p, TBC1D1 iso2 (mouse): S256‑p, TBC1D1 (rat): S256‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human

S507-p - TBC1D1 (human)
Modsite: AkRsLtEsLESILsR SwissProt Entrez-Gene
Orthologous residues
TBC1D1 (human): S507‑p, TBC1D1 iso2 (human): S507‑p, TBC1D1 (mouse): S501‑p, TBC1D1 iso2 (mouse): S501‑p, TBC1D1 (rat): S501‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human

S565-p - TBC1D1 (human)
Modsite: SsFKLLGssEDLssD SwissProt Entrez-Gene
Orthologous residues
TBC1D1 (human): S565‑p, TBC1D1 iso2 (human): S565‑p, TBC1D1 (mouse): S559‑p, TBC1D1 iso2 (mouse): S559‑p, TBC1D1 (rat): S559‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human

S566-p - TBC1D1 (human)
Modsite: sFKLLGssEDLssDs SwissProt Entrez-Gene
Orthologous residues
TBC1D1 (human): S566‑p, TBC1D1 iso2 (human): S566‑p, TBC1D1 (mouse): S560‑p, TBC1D1 iso2 (mouse): S560‑p, TBC1D1 (rat): S560‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human

S585-p - TBC1D1 (human)
Modsite: PEEPAPLsPQQAFRR SwissProt Entrez-Gene
Orthologous residues
TBC1D1 (human): S585‑p, TBC1D1 iso2 (human): S585‑p, TBC1D1 (mouse): S579‑p, TBC1D1 iso2 (mouse): S579‑p, TBC1D1 (rat): S579‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human

T596-p - TBC1D1 (human)
Modsite: AFRRRANtLsHFPIE SwissProt Entrez-Gene
Orthologous residues
TBC1D1 (human): T596‑p, TBC1D1 iso2 (human): T596‑p, TBC1D1 (mouse): T590‑p, TBC1D1 iso2 (mouse): T590‑p, TBC1D1 (rat): T590‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  human, rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Akt1 (human)
KINASE AMPKA1 (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
IGF-1 increase
LY294002 IGF-1 inhibit treatment-induced increase
wortmannin IGF-1 inhibit treatment-induced increase
calyculin_A increase
EGF increase
wortmannin EGF inhibit treatment-induced increase
Go_6983 EGF no effect upon treatment-induced increase
BI-D1870 EGF no effect upon treatment-induced increase
acadesine increase
compound_C acadesine inhibit treatment-induced increase
metformin acadesine inhibit treatment-induced increase
phenformin increase
phorbol_ester increase
wortmannin phorbol_ester no effect upon treatment-induced increase
Go_6983 phorbol_ester inhibit treatment-induced increase
BI-D1870 phorbol_ester inhibit treatment-induced increase
colforsin increase
A23187 increase
insulin increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
14-3-3 sigma (human) Induces far-Western, co-immunoprecipitation

S350-p - AS160 (rat)
Modsite: QPRRRHAsAPSHVQP GenPept Entrez-Gene
Orthologous residues
AS160 (human): S341‑p, AS160 iso2 (human): S341‑p, AS160 iso3 (human): S341‑p, AS160 (mouse): S348‑p, AS160 iso2 (mouse): S348‑p, AS160 (rat): S350‑p, AS160 (cow): S343‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  human, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
wortmannin insulin inhibit treatment-induced increase
A-769662 no change compared to control

T651-p - AS160 (rat)
Modsite: QFRRRAHtFSHPPSS GenPept Entrez-Gene
Orthologous residues
AS160 (human): T642‑p, AS160 iso2 (human): T642‑p, AS160 iso3 (human): T642‑p, AS160 (mouse): T649‑p, AS160 iso2 (mouse): T649‑p, AS160 (rat): T651‑p, AS160 (cow): T644‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  human, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
wortmannin insulin inhibit treatment-induced increase
A-769662 no change compared to control